#United States #New York #Securities Fraud #Pomerantz LLP #Gilead Sciences

Pomerantz Law Firm Investigates Investor Claims on Gilead Sciences

On July 27, 2025, Pomerantz LLP announced that it is actively investigating potential claims on behalf of investors of Gilead Sciences, Inc. (NASDAQ: GILD). The firm is particularly focused on whether Gilead and its directors or officers have engaged in securities fraud or other unlawful business practices. Investors are encouraged to reach out to Pomerantz for further information or to join a class action suit.

The investigation stems from a significant incident that occurred on June 10, 2025, when Gilead issued a press release disclosing that the U.S. Food and Drug Administration (FDA) had imposed a clinical hold on its HIV treatment trials involving two investigational drugs, GS-1720 and GS-4182. This clinical hold was a response to concerns raised about safety signals indicating decreases in CD4+ T-cell and lymphocyte counts among participants receiving the combination of these experimental treatments.

This news caused a sharp decline in Gilead's stock price, which fell by $2.91, representing a 2.58% drop, closing at $110.09 per share on the same day. This kind of negative information tends to raise red flags for investors, prompting investigations by law firms like Pomerantz LLP, which specializes in corporate and securities litigation. Investors believe they may have suffered losses due to the company’s alleged misconduct, which has now prompted further scrutiny.

Pomerantz LLP is recognized as one of the leading law firms in the field of corporate and securities litigation. Founded by Abraham L. Pomerantz, who is often referred to as the dean of the class action bar, the firm has a long history of advocating for investors' rights. Over the course of more than 85 years, Pomerantz has successfully represented victims of securities fraud, breaches of fiduciary duty, and corporate misconduct, securing numerous multimillion-dollar damages awards for those affected.

The firm has offices located in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv. Interested investors are encouraged to contact Danielle Peyton at Pomerantz LLP for more information on the ongoing investigation. The firm can be reached via email at [email protected] or by phone at 646-581-9980, extension 7980.

As always, it is essential for investors to remain vigilant and informed about their investment choices. Negative news regarding clinical trials not only affects the reputation of a company but can cause substantial financial losses. Hence, firms like Pomerantz play a vital role in investigating such matters to ensure accountability and justice for investors who may have been wronged.

In the fast-paced world of pharmaceuticals and investments, transparency and regulatory compliance are crucial. Actions taken by firms like Gilead in navigating these complexities are under constant scrutiny. As the investigation progresses, more information will likely be revealed concerning the claims against Gilead Sciences.

For those looking to stay updated on this investigation and other corporate legal matters, making use of resources provided by dedicated firms or staying in touch with investor advocacy groups can be instrumental in safeguarding one's investments.